Here is another knowledge level to contemplate within the back-and-forth about Pfizer’s antiviral capsule Paxlovid: A brand new evaluation discovered it may well meaningfully cut back COVID hospitalizations and deaths, even in these youthful than 65.
Why it issues: Paxlovid use surged over the summer season as a device to battle COVID, however it’s additionally confronted issues about contributing to COVID rebound, during which sufferers check optimistic or have signs days after a course of the drug is accomplished.
- One of many newest research, printed within the New England Journal of Medication, concluded that whereas the drug considerably benefited sufferers 65 and older, there was no proof of profit in youthful adults.
The main points: This evaluation, by the analysis arm of digital well being document firm Epic, checked out knowledge from greater than half 1,000,000 sufferers identified with COVID-19 between March and August.
- It discovered sufferers who acquired Paxlovid had been two instances much less more likely to be hospitalized for COVID and 4 instances much less more likely to die of the virus than those that did not.
- Totally vaccinated sufferers over the age of fifty who acquired the remedy had been about 3 times much less more likely to be hospitalized for COVID than those that did not.